| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/29/2001 | WO2001021151A1 Intranasal influenza virus vaccine |
| 03/29/2001 | WO2001021140A2 Cosmetic and/or pharmaceutical preparations |
| 03/29/2001 | WO2001021135A2 Polymer conjugates of ara-c and ara-c derivatives |
| 03/29/2001 | WO2001021008A2 Method for increasing pet activity |
| 03/29/2001 | WO2001020991A1 Phytochemicals for promoting weight loss |
| 03/29/2001 | WO2001020981A2 Anti-infective compositions for treating disordered tissue such as cold sores |
| 03/29/2001 | WO2001007067A3 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 03/29/2001 | WO2001007049A3 Ophthalmic composition comprising ketotifen |
| 03/29/2001 | WO2001002851A8 Method for screening targeting dds preparation |
| 03/29/2001 | WO2000061078A3 Sunscreen agents containing hydroxycarboxylic acid alkyl- and/or -alkenyloligoglycoside esters |
| 03/29/2001 | WO2000051576A3 Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain |
| 03/29/2001 | WO2000050089A3 Regulation of the stability of recombinant proteins and antiboodies |
| 03/29/2001 | WO2000032635A9 Tumor specific human monoclonal antibodies and methods of use |
| 03/29/2001 | WO2000032255A9 Polymeric coatings with controlled delivery of active agents |
| 03/29/2001 | WO1999062535A3 Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases |
| 03/29/2001 | DE19946184A1 Retinoid-containing emulsions with continuous water phase, for topical application e.g. for skin treatment, repair or renewal, having structured, polar, viscous oil phase to stabilize active agent |
| 03/29/2001 | DE19945982A1 Geschwindigkeitsbestimmte Partikel Certain particle velocity |
| 03/29/2001 | DE19944234A1 Transparent injectable liquid containing added dye, making the liquid level in a syringe more readily visible, e.g. by visually impaired diabetes patients |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2793128A1 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | CA2391976A1 Use of fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | CA2384829A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | CA2384812A1 Method and compositions for inhibiting adhesion formation |
| 03/29/2001 | CA2383629A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | CA2383589A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383413A1 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | CA2383240A1 Polymer conjugates of ara-c and ara-c derivatives |
| 03/29/2001 | CA2383131A1 Formulation |
| 03/29/2001 | CA2383110A1 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant |
| 03/29/2001 | CA2382834A1 Process for lessening polymorphic conversion of a drug |
| 03/29/2001 | CA2382547A1 Methods and compositions for treating platelet-related disosders |
| 03/29/2001 | CA2377525A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 03/29/2001 | CA2369515A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | CA2351673A1 Pharmaceutical antibacterial compositions |
| 03/28/2001 | EP1087011A2 Methods for preventing degradation of protein c |
| 03/28/2001 | EP1086945A1 Composition containing a cyclohexane derivative, compound and use thereof for structuring the composition |
| 03/28/2001 | EP1086706A1 Stabilized compositions containing nootropic drugs |
| 03/28/2001 | EP1086696A2 Immunopotentiating and infection protective agent and production thereof |
| 03/28/2001 | EP1086694A2 Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound |
| 03/28/2001 | EP1086693A1 Compositions containing proanthocyanidin and a vitamin B6 derivative or a salt thereof |
| 03/28/2001 | EP1086690A2 Pharmaceutical formulations of cefaclor |
| 03/28/2001 | EP1086689A2 Pharmaceutical formulations of cefaclor |
| 03/28/2001 | EP1086688A1 Suspension aerosol formulations |
| 03/28/2001 | EP1086239A1 Formulations for electroporation |
| 03/28/2001 | EP1086141A1 Aloe pectins |
| 03/28/2001 | EP1086126A1 Cell-permeable peptide |
| 03/28/2001 | EP1086120A1 Method for preparing virus-safe pharmaceutical compositions |
| 03/28/2001 | EP1086118A1 Vitamin b 12? derivatives and methods for their preparation |
| 03/28/2001 | EP1086065A4 Combinatorial synthesis of multibinding libraries |
| 03/28/2001 | EP1086065A1 Combinatorial synthesis of multibinding libraries |
| 03/28/2001 | EP1086063A1 Novel potassium channel drugs and their uses |
| 03/28/2001 | EP1085921A2 Antimicrobial alcohol gel pre-operative skin-preparation delivery systems |
| 03/28/2001 | EP1085909A2 Composition for the treatement of immune deficiencies and methods for its preparation and use |
| 03/28/2001 | EP1085908A2 Recombinant immunotoxin directed against the hiv-1 gp120 envelope glycoprotein |
| 03/28/2001 | EP1085907A1 Solution comprising prostaglandins and benzyl alcohol |
| 03/28/2001 | EP1085901A2 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
| 03/28/2001 | EP1085894A1 Beta 3-adrenergic receptor agonists |
| 03/28/2001 | EP1085893A1 Phosphodiesterase-v modulator drugs and their uses |
| 03/28/2001 | EP1085891A1 Multibinding inhibitors of topoisomerase |
| 03/28/2001 | EP1085890A1 Novel sodium channel drugs and uses |
| 03/28/2001 | EP1085889A2 Novel therapeutic agents that modulate endothelin receptors |
| 03/28/2001 | EP1085887A2 Novel angiotensin receptor modulators and their uses |
| 03/28/2001 | EP1085882A2 Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| 03/28/2001 | EP1085880A2 Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
| 03/28/2001 | EP1085879A2 Multibinding agents that modulate the 5-ht transporter |
| 03/28/2001 | EP1085878A2 Use of aminosterol derivatives as chloride ionophores |
| 03/28/2001 | EP1085870A2 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 03/28/2001 | EP1085868A1 H1-histamine receptor antagonists |
| 03/28/2001 | EP1085863A1 Cross-reference to related applications |
| 03/28/2001 | EP1085861A1 Inhibitors of nitric oxide synthase |
| 03/28/2001 | EP1085857A2 Cationic amphiphile micellar complexes |
| 03/28/2001 | EP1085856A2 Pressurized metered dose inhalers and pharmaceutical aerosol formulations comprising a beta-agonist |
| 03/28/2001 | EP1085855A1 Enhanced intra vaginal devices |
| 03/28/2001 | EP1085847A2 Novel therapeutic agents that modulate estrogen receptors |
| 03/28/2001 | EP1085846A2 Multibinding inhibitors of microsomal triglyceride transferase protein |
| 03/28/2001 | EP1085845A2 Multibinding inhibitors of cyclooxygenase-2 |
| 03/28/2001 | EP0921817B1 Pegylation process |
| 03/28/2001 | EP0921796B1 Tetrahydrolipstatin containing compositions |
| 03/28/2001 | EP0909166B1 Process for making a medicated chewing gum with a pleasant taste containing an inclusion complex |
| 03/28/2001 | EP0742714B1 Liquid pharmaceutical compositions comprising thyroid hormones |
| 03/28/2001 | EP0732922B1 Transdermal delivery device |
| 03/28/2001 | CN1289371A Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications |
| 03/28/2001 | CN1289259A Prostheses with associated growth factors |
| 03/28/2001 | CN1289256A Absorbable microparticles |
| 03/28/2001 | CN1289255A Process for making absorbable microparticles |
| 03/28/2001 | CN1289254A Compounds and methods for the treatment of bacterial dysentery using antibiotics and toxin binding oligosaccharide compositions |
| 03/28/2001 | CN1288729A Freeze dried lentinan holoside powder injecta and its preparation |
| 03/28/2001 | CN1288724A Qingkailing granule preparing process |
| 03/28/2001 | CN1288722A Tear-gland specific emulsion for local application to eye tissue |
| 03/28/2001 | CN1288688A Composition containing original flower pigment and vitamin B6 derivative or its salt |
| 03/28/2001 | CN1063630C Surface-modified anticancer nanopartiles |
| 03/28/2001 | CN1063629C Bioerodible controlled-release medicine delivery system |
| 03/27/2001 | US6207815 Dna coding for chimeric heavy chain or antigen binding fragment produced by specific cell lines; combines with high molecular weight, tumor-associated sialylated glycoprotein antigen light chain; diagnosis; imaging |
| 03/27/2001 | US6207805 Hybridoma which secretes monoclonal antibodies; diagnosis; anticarcinogenic agents with reduced side effects; imaging |
| 03/27/2001 | US6207802 Non-human, mammalian polypeptide of defined amino acid sequence which activates the growth of early hematopoietic progenitor cells; treatment of blood disorders; anticarcinogenic agents; bone marrow regeneration |
| 03/27/2001 | US6207798 Includes psuedomonas exotoxin-40 domain modified by replacement of at least two cysteines with alanines and a cell growth factor or hormone domain; targeted anticarcinogenic agents |
| 03/27/2001 | US6207749 Comb copolymers for regulating cell-surface interactions |
| 03/27/2001 | US6207718 Stability |